We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $2.17 | — | — | $1.32B | — | 예정 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-1.53 | — | — | $1.66B | 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.66 | — | — | $1.15B |
Consensus PT $445.81 · 27 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Citigroup | — | 커버리지 개시 | — → Buy | — | Citigroup: Buy |
| 2026. 05. 05. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q1 | 2024. 03. 31. | 시각 미정 | — | $-0.52 | — | — | $494.33M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,992,577 | $659.28B | 0.56% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 616,120 | $245B | 0.38% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny - simplywall.st
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) ChartMill
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes - Stock Titan
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes Stock Titan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - 富途牛牛
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 富途牛牛
Citi Initiates Alnylam (ALNY) With Buy Rating - Yahoo Finance
Citi Initiates Alnylam (ALNY) With Buy Rating Yahoo Finance